Literature DB >> 1918332

Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis.

S F Berkovic1, N K So, F Andermann.   

Abstract

Diagnosis and management of the progressive myoclonus epilepsies (PMEs) provides a challenge to the clinician and neurophysiologist. Over 15 specific disorders can cause the PME syndrome; all are rare, and individual physicians are unlikely to have experience in all of them. Accurate diagnosis is essential to provide a prognosis, optimal therapy, and genetic counseling. The major causes are PME of the Unverricht-Lundborg type, Lafora disease, neuronal ceroid lipofuscinoses (three forms), MERRF (myoclonus epilepsy and ragged red fibers), and sialidoses (two forms), in addition to a number of even rarer disorders. Here we review the clinical aspects and neurophysiology of these disorders, which can now be diagnosed in life by relatively simple methods in the vast majority of cases.

Entities:  

Mesh:

Year:  1991        PMID: 1918332

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  14 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

3.  A bioassay for Lafora disease and laforin glucan phosphatase activity.

Authors:  Amanda R Sherwood; Mary Beth Johnson; Antonio V Delgado-Escueta; Matthew S Gentry
Journal:  Clin Biochem       Date:  2013-09-06       Impact factor: 3.281

Review 4.  Lafora disease offers a unique window into neuronal glycogen metabolism.

Authors:  Matthew S Gentry; Joan J Guinovart; Berge A Minassian; Peter J Roach; Jose M Serratosa
Journal:  J Biol Chem       Date:  2018-02-26       Impact factor: 5.157

5.  Structural mechanism of laforin function in glycogen dephosphorylation and lafora disease.

Authors:  Madushi Raththagala; M Kathryn Brewer; Matthew W Parker; Amanda R Sherwood; Brian K Wong; Simon Hsu; Travis M Bridges; Bradley C Paasch; Lance M Hellman; Satrio Husodo; David A Meekins; Adam O Taylor; Benjamin D Turner; Kyle D Auger; Vikas V Dukhande; Srinivas Chakravarthy; Pascual Sanz; Virgil L Woods; Sheng Li; Craig W Vander Kooi; Matthew S Gentry
Journal:  Mol Cell       Date:  2014-12-24       Impact factor: 17.970

6.  Posterior paroxysmal discharge: an aid to early diagnosis in Lafora disease.

Authors:  S Ponsford; I F Pye; E J Elliot
Journal:  J R Soc Med       Date:  1993-10       Impact factor: 5.344

7.  Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG).

Authors:  Carolyn A Worby; Matthew S Gentry; Jack E Dixon
Journal:  J Biol Chem       Date:  2007-12-10       Impact factor: 5.157

8.  Laforin, a dual specificity phosphatase involved in Lafora disease, is present mainly as monomeric form with full phosphatase activity.

Authors:  Vikas V Dukhande; Devin M Rogers; Carlos Romá-Mateo; Jordi Donderis; Alberto Marina; Adam O Taylor; Pascual Sanz; Matthew S Gentry
Journal:  PLoS One       Date:  2011-08-26       Impact factor: 3.240

Review 9.  Lafora disease: insights into neurodegeneration from plant metabolism.

Authors:  Matthew S Gentry; Jack E Dixon; Carolyn A Worby
Journal:  Trends Biochem Sci       Date:  2009-10-07       Impact factor: 13.807

Review 10.  Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease.

Authors:  Pascual Sanz; José Maria Serratosa; Marina P Sánchez
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.